Mauer RF .1994 .The effect of Epoietin beta on the need for transfusion in very low birth weight infants. NEngJMed, 330 : 1173-8.
Ludwig H,Fritz E,Leitgeb C .1993 .et a! Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Annats ofOncol, 4 : 161-7.
. .Cardiovascular system in chronic renal failure. The impact of anemia and its correction with erythropoietin in Overview of literature related to erythropoietin 1993; 1-4. , : .
Al MomenAK,Garder AM .1991 .Low dose danazol is effective in management of erythropoietin induced thrombosis. ThrombPes, 64(5) : 527-32.
Savazi GM .1988 .Pathogenesis of cerebral atrophy in uremia. Nephron, 49 : 94-103.
Casati F,PasseriniP F .1987 .Benefits and risks of protracted treatment With human recombinant erythropoietin in-patients having hemodialysis. BMJ, 295 : 1017-20.
Abdul-Hadi NM .1989 .Recombinant human erythropoietin, correction of anemia dialysis efficiency, waste retention and chronic dose variables. ASA/0 Trans, 35 : 513-5.
EschbachJW. Ergie JC .1987 .DowningAIR Correction of anemia of end stage renal disease with recombinant human erythropoietin. NewEng JMed, 316 : 73-8.
Ganelloeras C,Leskopf W,Sheldon S,Forcade J . .Experience of pain after sub cutaneous administration of different preparation of Recombinant Human Erythropoietin: a randomized double blind cross over study. Ch'nNephro!\, 974 : 296.
Schaefer PM,Strauer RE,Heidland A .1988 .Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. AnnJNephro!, 8 : 449-53.
NonnastDaniel B. Crentzig A,Kuhn K .1988 .! Effort of treatment with recombinant human erythropoietin on peripheral hemodialysis and oxygenation. , 66 : 185-94.
Roger SD,Fluck RJ,Me MahonAC,Drawnay A,Raine ABG . .Blood pressure, erythropoietin and intracellular calcium in experimental hypertension and uremia. AbstractEDTA1992, : .
Yamakado M,Umezo M,Nagano M,Tagawa H M .1991 .Mechanism of hypertension induced by erythropoietin in-patients on hemodialysis. din Invest Med, 14(6) : 623-9.
Bode Boger SM,Boger RH,Kuhn M,Radermacher J,Frolich JC .1992 .Endothelin release and shift in prostaglandin balance are involved in modulation of vascular tone by recombinant human erythropoietin. J Cardio Vase Pharmacol, 20(Suppl 12) : .
.1987 .Recombinant human erythropoietin therapy in hemodialysis patients. Dose determination and clinical experience. NephrolDial Transplant, 2 : 238-42.
.1991 .Experience of erythropoietin in anemia of end stage renal disease. JPMA, 41 : 310-12.
.1994 .Once weekly sub cutaneous administration of erythropoietin in hemodialysis patients. JPMA, 44 : 88-90.
. .Effect of recombinant human erythropoietin therapy on blood pressure changes in hemodialysis. Am JNephrol 23-6, : .
El-Shahawy MA,Akmal M .1994 .eta! Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregration in hemodialysis patients. Clinical Nephrology, 41 : 308-13.
Eschbach JW,Dowing MR,Ergie JC,Browne JK,Adamson JW .1989 .USA Multicenter clinical trial with Recombinant Human Erythropoietin. , 76 : 160-5.
Pippard MJ,Hoffbrand V.,Iron V. .1999 .. In Postgraduate Haematology. 4th ed: Butterworth-Heinemann, : 33.
Tielmans C,Goldman M,Vanderweghem JL .1989 .Disorders of iron metabolism in uremic patients. Seminars in Dialysis, 2 : 163-71.
.2000 .Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients. Recommendations for a change in management. Am JKidDis, 35(6) : 1226-37.
Walker R .1999 .general management of end stage renal disease. 2®fc. , : 1429-32.
Krantz AT .1999 .Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kid Dis, 34(4) : 688-93.
Tarng DC . .HuangTP. Recombinant human erythropoietin resistance in iron replete hemodialysis patients: role of Aluminum toxicity. Am J Nephrol, 8(1) : 1-8.